Molecules that block viral infectivity and methods of use thereof

Abstract

Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

1 . A method of inhibiting replication of HIV comprising: 
 providing a composition that comprises a therapeutically effective amount of monpeptidic glycine amide to a subject in need thereof.    
     
     
         2 . The method of  claim 1 , wherein said composition further comprises a compound that inhibits replication of HIV in the presence of monopeptidic glycine amide.  
     
     
         3 . The method of  claim 1 , further comprising the step of providing a compound that inhibits replication of HIV in the presence of monopeptidic glycine amide to said subject in need thereof.  
     
     
         4 . The method of  claim 1 , wherein said subject in need thereof is a human infected with HIV.  
     
     
         5 . The method of  claim 1 , wherein said subject in need thereof is a human that is at risk of being infected with HIV.  
     
     
         6 . The method of  claim 1 , wherein said monpeptidic glycine amide is formulated for oral administration.  
     
     
         7 . The method of  claim 2 , wherein said monpeptidic glycinamide and said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide are formulated for oral administration.  
     
     
         8 . The method of  claim 3 , wherein said monpeptidic glycinamide and said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide are formulated for oral administration.  
     
     
         9 . The method of  claim 2 , further comprising the step of identifying said subject as a human infected with HIV.  
     
     
         10 . The method of  claim 3 , further comprising the step of identifying said subject as a human that is at risk of being infected with HIV.  
     
     
         11 . The method of  claim 1 , further comprising the step of measuring the inhibition of HIV infection.  
     
     
         12 . The method of  claim 2 , further comprising the step of measuring the inhibition of HIV infection.  
     
     
         13 . The method of  claim 3 , further comprising the step of measuring the inhibition of HIV infection.  
     
     
         14 . The method of  claim 9 , further comprising the step of measuring the inhibition of HIV infection.  
     
     
         15 . The method of  claim 10 , further comprising the step of measuring the inhibition of HIV infection.  
     
     
         16 . The method of  claim 2 , wherein said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide is a peptide.  
     
     
         17 . The method of  claim 3 , wherein said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide is a peptide.  
     
     
         18 . The method of  claim 16 , wherein said peptide is selected from the group consisting of AIG-NH 2 , GFG-NH 2 , GWG-NH 2 , FLG-NH 2 , GYG-NH 2 , APG-NH 2 , GLG-NH 2 , and alpha-t-butylglycine-PG-NH 2 .  
     
     
         19 . The method of  claim 17 , wherein said peptide is selected from the group consisting of AIG-NH 2 , GFG-NH 2 , GWG-NH 2 , FLG-NH 2 , GYG-NH 2 , APG-NH 2 , GLG-NH 2 , and alpha-t-butylglycine-PG-NH 2 .  
     
     
         20 . The method of  claim 2 , wherein said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide is selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors.  
     
     
         21 . The method of  claim 3 , wherein said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide is selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors.  
     
     
         22 . The method of  claim 20 , wherein said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide is selected from the group consisting of azidothymidine (AZT), zidovudine, lamivudine, stavudine, didanosine, abacavir, zalcitabine, adetovir, pivaxir, efavirenz, nevirapine, delavirdine, indinavir, nelfinavir, ritonavir, saquinavir, and amprenavir.  
     
     
         23 . The method of  claim 21 , wherein said compound that inhibits replication of HIV in the presence of monopeptidic glycine amide is selected from the group consisting of azidothymidine (AZT), zidovudine, lamivudine, stavudine, didanosine, abacavir, zalcitabine, adetovir, pivaxir, efavirenz, nevirapine, delavirdine, indinavir, nelfinavir, ritonavir, saquinavir, and amprenavir.